Rockville gene therapy company to begin trials for treatment for leading cause of blindness – Washington Business Journal
Washington Business Journal |
Rockville gene therapy company to begin trials for treatment for leading cause of blindness
Washington Business Journal Rockville-based RegenxBio Inc. has received Food and Drug Administration approval to begin clinical trials of its gene therapy to treat wet age-related macular degeneration, a leading cause of blindness. RegenxBio's gene therapy technology introduces … |
